Hengrui Medicine (01276): Injection of Rucanlizumab's third indication has been approved for market launch.

Zhixin Finance APP reports that Heng Rui Medicine (01276) announced that recently, its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. received a notification from the National Medical Products Administration, stating that the third indication for the injectable Trastuzumab deruxtecan has been approved for marketing, making it the first anti-HER2 product approved for colorectal cancer in China.